The recent article by Skaaby and colleagues (1) reported that there were no significant associations between baseline serum 25-hydroxyvitamin D [25(OH)D] levels and incident internal cancer rates during an 11.3-year median follow-up time. One reason for the failure to find significant associations is the long follow-up time, mentioned in passing in the article. This effect has been studied with the finding that for follow-up times greater than 4 years for breast cancer and 13 years for colorectal cancer it is very unlikely to find significant inverse associations due to changes in 25(OH)D levels (2). Mean serum 25(OH)D levels for like-age populations in their study decreased from 65 nmol/L in 1993–4 to 52 nmol/L in 1999–2001 and 44 nmol/L in 2006–8 (Table 2 in ref. 1). Thus, the 25(OH)D levels of the Monica10 and Inter99 cohorts, representing 90% of incident cancers, were not constant during the follow-up period.

Another problem is that a linear relation between serum 25(OH)D level and risk of cancer incidence was assumed. As shown in meta-analyses of breast and colorectal cancer incidence rates with respect to serum 25(OH)D level, the relation is nonlinear, with rapid decrease for small increases from low 25(OH)D levels and little change for increases beyond 70 nmol/L (3).

Although prospective population studies have found mixed associations between baseline serum 25(OH)D levels and cancer incidence rates, ecologic and occupation studies have found very strong inverse associations between indices of solar ultraviolet B (UVB) doses and cancer incidence and/or mortality rates (4, 5). The advantages of such studies include the large number of cases, the fact that people have generally lived in the same location for many years so that the UVB index is applicable for a long period, and that many other cancer risk–modifying factors can generally be included in the analysis. Such studies have found significant inverse correlations between solar UVB indices and 20 types of cancer, with nine types being found in at least four different countries or regions: bladder, breast, colon, esophageal, gall bladder, gastric, pancreatic, rectal cancer, and leukemia (4). A possible drawback to such studies is that there may be effects of solar UVB irradiance in reducing risk of cancer in addition to production of vitamin D; however, no mechanisms have been proposed to explain other UVB effects for cancer risk. The mechanisms whereby vitamin D reduces the risk of cancer incidence, progression, and metastasis are well known (4).

See the Response, p. 1951

W.B. Grant reports receiving a commercial research grant from Bio-Tech Pharmacal and The Sunlight Research Forum (Veldhoven).

1.
Skaaby
T
,
Husemoen
LL
,
Thuesen
BH
,
Pisinger
C
,
Jørgensen
T
,
Roswall
N
, et al
Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer
.
Cancer Epidemiol Biomarkers Prev
2014
;
23
:
1220
9
.
2.
Grant
WB
. 
Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level; implications for meta-analyses and setting vitamin D guidelines
.
Dermatoendocrinol
2011
;
3
:
199
204
.
3.
Grant
WB
. 
Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers
.
J Photochem Photobiol B
2010
;
101
:
130
6
.
4.
Moukayed
M
,
Grant
WB
. 
Molecular link between vitamin D and cancer prevention
.
Nutrients
2013
;
5
:
3993
4023
.
5.
Grant
WB
. 
Role of solar UV irradiance and smoking in cancer as inferred from cancer incidence rates by occupation in Nordic countries
.
Dermatoendocrinol
2012
;
4
:
203
11
.